ritonavir accord 100 mg
accord healthcare limited - marea britanie - ritonavirum - compr. film. - 100mg - antivirale cu actiune directa inhibitori de proteaza
ritonavir accord 100 mg
pharmadox healthcare ltd. - malta - ritonavirum - compr. film. - 100mg - antivirale cu actiune directa inhibitori de proteaza
ritonavir sandoz 100 mg
pharmadox healthcare ltd. - malta - ritonavirum - compr. film. - 100mg - antivirale cu actiune directa inhibitori de proteaza
invega comprimate cu eliberare prelungita 6 mg
janssen-cilag international nv - paliperidonum - comprimate cu eliberare prelungita - 6 mg
meaxin 100 mg
krka, d.d. novo mesto - slovenia - imatinibum - compr. disp. - 100mg - alte antineoplazice inhibitori de protein-kinaza
meaxin 400 mg
krka, d.d. novo mesto - slovenia - imatinibum - compr. disp. - 400mg - alte antineoplazice inhibitori de protein-kinaza
ritonavir aurobindo 100 mg
apl swift services (malta) ltd. - malta - ritonavirum - compr. film. - 100mg - antivirale cu actiune directa inhibitori de proteaza
noflamen 7,5 mg
egis pharmaceuticals plc - ungaria - meloxicamum - compr. - 7,5mg - antiinflamatoare si antireumatice nesteroidiene oxicami
noflamen 15 mg
egis pharmaceuticals plc - ungaria - meloxicamum - compr. - 15mg - antiinflamatoare si antireumatice nesteroidiene oxicami
yervoy
bristol-myers squibb pharma eeig - ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - agenți antineoplazici - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4. yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 și 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.